| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
10(Z)-Pentadecenoic acid does not have a defined biological target as it is a fatty acid standard and research reagent rather than a pharmacologically active drug. However, it has been shown to inhibit IFN-γ-induced production of kynurenine in Thp-1 cells by 16%. This suggests potential immunomodulatory activity through interference with the kynurenine pathway, which is involved in tryptophan metabolism and immune regulation. As a fatty acid, it may also interact with fatty acid-binding proteins and membrane lipid bilayers through hydrophobic interactions.
|
|---|---|
| ln Vitro |
In vitro, 10(Z)-pentadecenoic acid inhibits IFN-γ-induced production of kynurenine in Thp-1 cells by 16%. This activity suggests that the compound may modulate immune responses by affecting the kynurenine pathway, which is upregulated by pro-inflammatory cytokines such as IFN-γ. As a fatty acid, it may also be incorporated into cellular membranes and affect membrane fluidity and signaling. The compound is primarily used as a high-purity lipid standard for analytical and biochemical research.
|
| ln Vivo |
10(Z)-Pentadecenoic acid is not a pharmacologically approved drug and does not exhibit established in vivo therapeutic activity. Its primary use is as a research reagent and lipid standard for analytical biochemistry. The compound has not been evaluated in animal models for efficacy against any disease. Any in vivo effects would be associated with its role as a fatty acid in lipid metabolism and immune modulation. The compound is not intended for human or veterinary use.
|
| Enzyme Assay |
In vitro assays for 10(Z)-pentadecenoic acid focus on its biological activity and use as a fatty acid standard. A standard protocol for kynurenine inhibition studies involves culturing Thp-1 cells (human monocytic leukemia cells) and treating them with IFN-γ (typically 10-100 ng/mL) in the presence of varying concentrations of the fatty acid (typically 1-100 µM). After 24-48 hours of incubation, kynurenine levels in the culture supernatant are measured by HPLC or ELISA. For lipid analysis applications, the compound is used as a chromatographic standard for the identification and quantification of fatty acids by GC or LC-MS.
|
| Cell Assay |
In vitro cell culture experiments with 10(Z)-pentadecenoic acid typically involve immune cells such as Thp-1 cells to study its effects on the kynurenine pathway. Cells are cultured in RPMI medium supplemented with 10% FBS and treated with the fatty acid at concentrations ranging from 1-100 µM for 24-48 hours. Kynurenine production is induced by IFN-γ stimulation. Cell viability is assessed using MTT assays to ensure that observed effects are not due to cytotoxicity. The compound is also used in studies of fatty acid metabolism and lipid signaling in various cell types.
|
| Animal Protocol |
In vivo animal studies with 10(Z)-pentadecenoic acid are not well documented, as the compound is primarily used as a research reagent and lipid standard. If conducted, typical protocols for fatty acid administration would involve oral gavage or intravenous injection in rodents at doses ranging from 10-100 mg/kg. Blood samples would be collected for pharmacokinetic analysis and lipid profiling. However, such studies are not standard for this compound as it is not a drug candidate. The compound is not used in efficacy studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 10(Z)-pentadecenoic acid are not well characterized as it is not a drug substance. As a long-chain monounsaturated fatty acid with a molecular weight of 240.38 and high lipophilicity, the compound would be expected to be absorbed through the gastrointestinal tract via incorporation into chylomicrons. Following absorption, it would be distributed to various tissues, incorporated into cellular membranes, and metabolized via β-oxidation. The compound has low water solubility. No formal ADME studies have been conducted.
|
| Toxicity/Toxicokinetics |
Toxicological data for 10(Z)-pentadecenoic acid are limited as it is a research reagent. As a naturally occurring fatty acid, it is generally considered to have low toxicity at normal dietary levels. Standard laboratory precautions should be followed when handling the compound, including the use of gloves and safety glasses. The compound should be stored at -20°C. The compound is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
Cis-10-pentadecanenoic acid is the cis isomer of pentadecanoic acid and is a metabolite.
It has been reported that 10Z-pentadecanenoic acid has been detected in Pyrococcus furiosus, and relevant data are available for reference. 10(Z)-Pentadecenoic acid is a 15-carbon, long-chain monounsaturated fatty acid used as a high-purity lipid standard for analytical and biochemical research. It is also known as FA 15:1 and cis-10-pentadecenoic acid. The compound inhibits IFN-γ-induced production of kynurenine in Thp-1 cells by 16%. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action may involve modulation of the kynurenine pathway and immune responses. |
| Molecular Formula |
C15H28O2
|
|---|---|
| Molecular Weight |
240.38
|
| Exact Mass |
240.209
|
| CAS # |
84743-29-3
|
| Related CAS # |
10(E)-Pentadecenoic acid;321744-58-5
|
| PubChem CID |
5312411
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
4.938
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
17
|
| Complexity |
197
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCCCCC(=O)O)CC/C=C\CCCC
|
| InChi Key |
APXSAEQXOXTDAM-WAYWQWQTSA-N
|
| InChi Code |
InChI=1S/C15H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(16)17/h5-6H,2-4,7-14H2,1H3,(H,16,17)/b6-5-
|
| Chemical Name |
(Z)-pentadec-10-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (416.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1601 mL | 20.8004 mL | 41.6008 mL | |
| 5 mM | 0.8320 mL | 4.1601 mL | 8.3202 mL | |
| 10 mM | 0.4160 mL | 2.0800 mL | 4.1601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
